← Back to Search

Cannabinoid

THC for Driving Performance

Phase < 1
Recruiting
Led By Heather Barkholtz, PhD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 18 years of age, no older than 49 years of age
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months

Summary

This trial aims to study the effects of different forms of THC on the body and driving performance. They will use standardized doses of THC to measure how it affects the body and driving abilities compared to a placebo

Who is the study for?
This trial is for people aged 18-49 who have used cannabis in the last two years, are in good mental health, don't have major medical issues, speak English, and can drive (with a valid license and at least two years of experience).
What is being tested?
The study tests how Δ9-THC and Δ8-THC affect driving. Participants will receive either one of these cannabis compounds or a placebo to see how it impacts their driving skills using standardized dosing and impairment detection methods.
What are the potential side effects?
Possible side effects from Δ9-THC or Δ8-THC may include delayed reaction times, impaired motor coordination, altered judgment, difficulty concentrating or remembering things.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 49 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Quantify analyte concentrations
Quantify impairing effects of cannabinoids

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: delta-9-THCExperimental Treatment1 Intervention
Group II: delta-8-THCExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Delta-9-THC
2021
Completed Early Phase 1
~70

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,231 Previous Clinical Trials
3,199,880 Total Patients Enrolled
Heather Barkholtz, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison
~3 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top